Role of cytoreduction and hyperthermic intraperitoneal chemotherapy for metastatic gastroesophageal junction adenocarcinoma?

Autor: Zaidi SMH; King Edward Medical University, Department of Medicine, Lahore, Pakistan., Ho K; NYU Long Island School of Medicine, Department of Surgery, Mineola, NY, United States., Sohail AH; NYU Long Island School of Medicine, Department of Surgery, Mineola, NY, United States., Whittington J; NYU Long Island School of Medicine, Department of Surgery, Mineola, NY, United States.
Jazyk: angličtina
Zdroj: Journal of surgical case reports [J Surg Case Rep] 2023 Dec 06; Vol. 2023 (12), pp. rjad664. Date of Electronic Publication: 2023 Dec 06 (Print Publication: 2023).
DOI: 10.1093/jscr/rjad664
Abstrakt: Gastric cancer is the fifth most prevalent cancer worldwide and the third leading cause of cancer- related mortality. Peritoneal carcinomatosis can develop in patients with a primary gastric tumor in a substantial proportion of patients, with estimates ranging from 14% to 43%. For patients with peritoneal carcinomatosis from gastric cancer, therapeutic options are limited. Intraperitoneal chemotherapy, combined with hyperthermia (HIPEC), provides regional dose intensification within the peritoneal cavity, effectively targeting peritoneal carcinomatosis with minimal systemic exposure. We report a case of gastroesophageal junction adenocarcinoma with peritoneal metastasis successfully treated with of cytoreductive surgery and HIPEC, and followed by surgery and systemic chemotherapy, highlighting HIPEC as one of the viable options and the importance of a multimodal approach for the treatment of this case.
Competing Interests: None declared.
(Published by Oxford University Press and JSCR Publishing Ltd. © The Author(s) 2023.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje